Suppr超能文献

基因预测的铁补充剂药物靶点与炎症性肠病之间的相关性:一项孟德尔随机化研究。

Correlations between genetically predicted iron-supplement drug targets and inflammatory bowel disease: A Mendelian randomization study.

作者信息

Li Dong-Lin, Jiang Chuan, Guan Zhong-An, Ma Ling-Ling, Cui Wen-Wen

机构信息

First School of Clinical Medicine, Shandong Traditional Chinese Medicine University, Jinan, Shandong Province, China.

Department of Proctology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China.

出版信息

Medicine (Baltimore). 2025 Jun 13;104(24):e42729. doi: 10.1097/MD.0000000000042729.

Abstract

This study investigates the causal relationship between genetically proxied iron-supplement drugs and inflammatory bowel disease (IBD) risk. After identifying 8 commonly used iron supplementation drugs based on the guidelines, a search for each of these drugs yielded 18 key regulatory targets and the locus information of each drug-targeted gene was obtained. Hemoglobin was selected as a biomarker downstream of drug regulation and its single nucleotide polymorphism (SNP) data were extracted and screened from genome-wide association studies (GWAS). Strict screening conditions were set to obtain valid SNPs information for each drug-target gene from hemoglobin downstream marker information. We successively included European and Asian populations in our analyses. The SNP information of IBD, ulcerative colitis (UC) and Crohn disease (CD) were extracted from the GWAS database as the outcome variables. The bidirectional and multivariate Mendelian randomization was performed between each target gene and each outcome variable, and the robustness of these results was validated using heterogeneity tests, horizontal pleiotropy tests, and leave-one-out methods. Data from 34,652 patients with IBD, 417,932 patients with UC, 20,883 patients with CD, and 408,112 individuals with hemoglobin measurement were analyzed. Genetically proxied Egl nine homolog 1 (EGLN1) was associated with increased IBD, UC and CD risk. Genetically proxied Flap Endonuclease 1 (FEN1) was associated with an increased risk of IBD and CD. Genetically proxied Ferritin heavy chain 1 (FTH1) and Transferrin receptor 2 (TFR2) were associated with an increased risk of CD. Genetically proxied DNA polymerase beta (POLB) was associated with a reduced risk of CD. Sensitivity analyses of them did not provide statistical evidence of serious bias. The reverse Mendelian results showed a positive result between IBD and EGLN1, meaning that there is a bidirectional causal relationship between the 2. Upon inclusion of the Asian ethnic cohort, potential causal associations were found between EGLN1, FEN1, Integrin, beta 3 (ITGB3), Transferrin receptor gene (TFRC) and UC, inverse Mendelian analyses showed a causal relationship between POLB and CD. This study suggests that target genes such as EGLN1, FEN1, ITGB3, TFRC, FTH1, and POLB are potentially associated with the pathogenesis of inflammatory bowel disease.

摘要

本研究调查了基因代理的补铁药物与炎症性肠病(IBD)风险之间的因果关系。根据指南确定8种常用补铁药物后,对每种药物进行检索得到18个关键调控靶点,并获取了每个药物靶向基因的基因座信息。选择血红蛋白作为药物调控下游的生物标志物,并从全基因组关联研究(GWAS)中提取和筛选其单核苷酸多态性(SNP)数据。设置严格的筛选条件,从血红蛋白下游标记信息中获取每个药物靶向基因的有效SNP信息。我们在分析中先后纳入了欧洲和亚洲人群。从GWAS数据库中提取IBD、溃疡性结肠炎(UC)和克罗恩病(CD)的SNP信息作为结果变量。在每个靶基因与每个结果变量之间进行双向和多变量孟德尔随机化,并使用异质性检验、水平多效性检验和留一法验证这些结果的稳健性。分析了来自34652例IBD患者、417932例UC患者、20883例CD患者以及408112例有血红蛋白测量值个体的数据。基因代理的缺氧诱导因子脯氨酰羟化酶1(EGLN1)与IBD、UC和CD风险增加相关。基因代理的瓣内切酶1(FEN1)与IBD和CD风险增加相关。基因代理的铁蛋白重链1(FTH1)和转铁蛋白受体2(TFR2)与CD风险增加相关。基因代理的DNA聚合酶β(POLB)与CD风险降低相关。对它们的敏感性分析未提供严重偏倚的统计学证据。反向孟德尔结果显示IBD与EGLN1之间呈阳性结果,意味着两者之间存在双向因果关系。纳入亚洲种族队列后,发现EGLN1、FEN1、整合素β3(ITGB3)、转铁蛋白受体基因(TFRC)与UC之间存在潜在因果关联,反向孟德尔分析显示POLB与CD之间存在因果关系。本研究表明,EGLN1、FEN1、ITGB3、TFRC、FTH1和POLB等靶基因可能与炎症性肠病的发病机制相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7b0/12173267/c6bdf1087361/medi-104-e42729-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验